With robust three-month efficiency and important upside potential, Compass Therapeutics, Inc. (NASDAQ:CMPX) secures a spot on our listing of the 12 sizzling penny shares to put money into proper now.
A physician in a lab coat holding a healthcare resolution of their arms.
On November 10, 2025, H.C. Wainwright’s Joseph Pantginis reiterated a “Purchase” score on Compass Therapeutics, Inc. (NASDAQ:CMPX) with a $24 worth goal. The corporate’s advancing pipeline, marked by the preclinical progress of CTX-10726, gained the analyst’s confidence, who was significantly impressed with the bispecific antibody’s substantial potential. At SITC 2025, the drug demonstrated high-affinity goal engagement and sturdy anti-tumor exercise. The analyst additionally cited the molecule’s aggressive edge over brokers comparable to ivonescimab and bevacizumab, reinforcing optimism as its deliberate Part 1 trial in 2026 comes nearer.
In the meantime, Compass Therapeutics, Inc. (NASDAQ:CMPX) reported Q3 2025 outcomes on November 5. The money stability reached $220 million by the top of Q3, which can assist operations by means of 2028. G&A bills recorded a considerable enhance, rising from $8.6 million in Q3 2024 to $12.8 million. Administration additionally reiterated its expectations to ship general survival (OS) and progression-free survival (PFS) knowledge for tovecimig in late Q1 2026. This might probably assist the corporate’s first BLA submitting within the second half of 2026. On the identical time, Compass reported encouraging leads to the Part 1 examine of CTX-8371. The corporate recorded a web lack of $14.3 million, or $0.08 per share, for the quarter.
Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage oncology firm, develops antibody-based therapies concentrating on angiogenesis, immune activation, and tumor evasion pathways.
Whereas we acknowledge the potential of CMPX as an funding, we consider sure AI shares supply better upside potential and carry much less draw back danger. In the event you’re in search of an especially undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring development, see our free report on the finest short-term AI inventory.
READ NEXT: 10 Greatest Small-Cap Biotech Shares to Purchase In keeping with Analysts and 11 Neglected Tech Shares to Make investments In.
Disclosure: None.
